Information Provided By:
Fly News Breaks for August 9, 2018
ENDP
Aug 9, 2018 | 09:13 EDT
Leerink analyst Ami Fadia raised her price target for Endo to $18 from $12 as its business continues to perform with strength from both Xiaflex and the Sterile Injectables segment, which were the key contributors to management's improved outlook for 2018. The analyst continues to see the business well positioned to deliver against management's new guidance and also look for the Phase 3 Cellulite data for CCH in Q4 and improved visibility into the Somerset/Nevakar assets to continue to drive near-term momentum in the stock. Fadia reiterates an Outperform rating on the shares.
News For ENDP From the Last 2 Days
There are no results for your query ENDP